ads

PTC Therapeutics Nearly Doubles Pre-Market on Optimism for Update on Translarna Re-Examination by European Medicines Agency

PTC Therapeutics Nearly Doubles Pre-Market on Optimism for Update on Translarna Re-Examination by European Medicines Agency

PTC Therapeutics (PTCT) shares surged in Friday's pre-market session, nearly doubling after the biopharmaceutical company said it would provide an update via a conference call later Friday morning on the re-examination of its marketing authorization application to the European Medicines Agency for conditional marketing authorization of Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy. The conference call will be held at 8:30 a.m. ET Friday. Upon the company's announcement of the call, the shares soared, up 96% in recent pre-market trading to $30, as investors registered their optimism for the coming update. The stock has a 52-week range of $13.03 to $34.65.

PTC Therapeutics Nearly Doubles Pre-Market on Optimism for Update on Translarna Re-Examination by European Medicines Agency